基于靶向腺苷途径和PD-1/PDL-1轴的结合癌症免疫疗法
Combined cancer immunotherapy based on targeting adenosine pathway and PD-1/PDL-1 axis
影响因子:4.40000
分区:医学2区 / 药学2区
发表日期:2024 Sep
作者:
Mehrdad Fathi, Asieh Zarei, Ata Moghimi, Pooya Jalali, Zahra Salehi, Sharareh Gholamin, Farhad Jadidi-Niaragh
摘要
癌症免疫疗法彻底改变了肿瘤学领域，为晚期恶性肿瘤的患者提供了新的希望。肿瘤诱导的免疫抑制限制了当前免疫治疗策略的有效性，例如PD-1/PDL-1检查点抑制剂。腺苷是一种嘌呤核苷分子，对这种免疫抑制至关重要，因为它可以阻止T细胞激活并有助于调节T细胞生长。靶向腺苷途径和阻塞PD-1/PDL-1是提高免疫系统对肿瘤反应的潜在方法。本文讨论了当前对肿瘤免疫学中腺苷途径的理解，以及支持腺苷途径抑制剂与PD-1/PDL-1封闭剂的组合的临床前和临床数据。我们还讨论了针对腺苷途径和PD-1/PDL-1轴进行癌症治疗的组合免疫疗法的挑战和未来方向。腺苷信号通路控制许多免疫系统过程的事实表明，它具有广泛的治疗用途。在接下来的五年内，该领域将取得巨大进展，治疗恶性肿瘤的护理标准将从点对点治疗转换为由多个信号通路（例如腺苷轴）组成的免疫网络的整合。
Abstract
Cancer immunotherapy has revolutionized the field of oncology, offering new hope to patients with advanced malignancies. Tumor-induced immunosuppression limits the effectiveness of current immunotherapeutic strategies, such as PD-1/PDL-1 checkpoint inhibitors. Adenosine, a purine nucleoside molecule, is crucial to this immunosuppression because it stops T cells from activating and helps regulatory T cells grow. Targeting the adenosine pathway and blocking PD-1/PDL-1 is a potential way to boost the immune system's response to tumors.This review discusses the current understanding of the adenosine pathway in tumor immunology and the preclinical and clinical data supporting the combination of adenosine pathway inhibitors with PD-1/PDL-1 blockade. We also discuss the challenges and future directions for developing combination immunotherapy targeting the adenosine pathway and the PD-1/PDL-1 axis for cancer treatment.The fact that the adenosine signaling pathway controls many immune system processes suggests that it has a wide range of therapeutic uses. Within the next five years, there will be tremendous progress in this area, and the standard of care for treating malignant tumors will have switched from point-to-point therapy to the integration of immunological networks comprised of multiple signaling pathways, like the adenosine axis.